Paul Tudor Jones Protagonist Therapeutics, Inc Transaction History
Tudor Investment Corp Et Al
- $15.5 Billion
- Q1 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 22,510 shares of PTGX stock, worth $713,792. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,510
Previous 28,786
21.8%
Holding current value
$713,792
Previous $660,000
1.36%
% of portfolio
0.0%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding PTGX
# of Institutions
188Shares Held
59.5MCall Options Held
35.7KPut Options Held
72.3K-
Farallon Capital Management LLC San Francisco, CA5.74MShares$182 Million0.77% of portfolio
-
Black Rock Inc. New York, NY5.57MShares$177 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.32MShares$169 Million2.47% of portfolio
-
Bvf Inc San Francisco, CA3.76MShares$119 Million3.25% of portfolio
-
State Street Corp Boston, MA3.27MShares$104 Million0.0% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.56B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...